Alkem Laboratories Limited

rs,

.com 25 th May, 2021 The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523 National Stock Exchange oflndia Limited Exchan

21,922 million

mbai today. Key highlights of Q4FY21 financial performance • Total Revenue from Operations was~ 21,922 million, year-on-year growth of 7.0% o o India sales were~ 14,732 million, year-on-year growth of 17.

7.0%

financial performance • Total Revenue from Operations was~ 21,922 million, year-on-year growth of 7.0% o o India sales were~ 14,732 million, year-on-year growth of 17.1% International sales were

14,732 million

evenue from Operations was~ 21,922 million, year-on-year growth of 7.0% o o India sales were~ 14,732 million, year-on-year growth of 17.1% International sales were~ 6,907 million, year-on-year decline of 8.

17.1%

ion, year-on-year growth of 7.0% o o India sales were~ 14,732 million, year-on-year growth of 17.1% International sales were~ 6,907 million, year-on-year decline of 8.2% • Earnings before Interes

6,907 million

o o India sales were~ 14,732 million, year-on-year growth of 17.1% International sales were~ 6,907 million, year-on-year decline of 8.2% • Earnings before Interest, Tax, Depreciation and Amortization (EBI

8.2%

on, year-on-year growth of 17.1% International sales were~ 6,907 million, year-on-year decline of 8.2% • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ~ 2,911 million, re

2,911 million

ear decline of 8.2% • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ~ 2,911 million, resulting in EBITDA margin of 13.3% vs. 14.8% in Q4FY20. EBITDA declined by 3.9% YoY • R&D exp

13.3%

t, Tax, Depreciation and Amortization (EBITDA) was ~ 2,911 million, resulting in EBITDA margin of 13.3% vs. 14.8% in Q4FY20. EBITDA declined by 3.9% YoY • R&D expenses for the quarter was ~ 1,408 milli

14.8%

preciation and Amortization (EBITDA) was ~ 2,911 million, resulting in EBITDA margin of 13.3% vs. 14.8% in Q4FY20. EBITDA declined by 3.9% YoY • R&D expenses for the quarter was ~ 1,408 million, or 6.4

3.9%

was ~ 2,911 million, resulting in EBITDA margin of 13.3% vs. 14.8% in Q4FY20. EBITDA declined by 3.9% YoY • R&D expenses for the quarter was ~ 1,408 million, or 6.4% of total revenue from operations

1,408 million

in of 13.3% vs. 14.8% in Q4FY20. EBITDA declined by 3.9% YoY • R&D expenses for the quarter was ~ 1,408 million, or 6.4% of total revenue from operations compared to~ 1,253 million in Q4FY20 at 6.1% of total r

Details of the conference call are as under

1

Dial in Details

1

Dial in Details

India : +91 22 6280 1149 / +91 22 7115 8050 International Toll Free USA UK Singapore Hong Kong : 1 866 746 2133 : 0 808 101 1573 : 800 101 2045 : 800 964 448 Express Join with Diamond Pass https:/ /services .choru scall . in/Diam and Pass Registration/register?confirm at ion Nu m ber=57 443 73&1 inkS ecu rityStri ng=13c7a00789 You are requested to dial in 10 mins ahead of the scheduled start time. A transcript of this conference call will also be available on our website www.alkemlabs .com About Alkem La boratories Ltd. Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters : ALKE.NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale or µhdr rndt:eulical and nutraceutical products. The Company produces branded generics, generic drues, ;ictivP pharmaceutical ingredients (APls) and nutraceuticals, which it markets in India and International markets. With a portfolio of